New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
09:06 EDTABBV, SGENSeattle Genetics further expands ADC collaboration with AbbVie
Seattle Genetics (SGEN) announced that it has further expanded its antibody-drug conjugate collaboration with AbbVie (ABBV). Under the expanded deal, AbbVie will pay an upfront fee of $25M for additional rights to utilize Seattle Genetics’ ADC technology with AbbVie antibodies against oncology targets, including access to Seattle Genetics’ pyrrolobenzodiazepine dimer ADC technology and EC-mAb site-specific conjugation technology. In addition, Seattle Genetics could receive up to approximately $255M in potential license fees and milestone payments per target, upon achieving predetermined development and commercial objectives, as well as mid-to-high single-digit royalties on worldwide net sales of any resulting products.
News For SGEN;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 22, 2014
09:19 EDTABBVHigher than expected Abbvie HCV drug pricing positive for Gilead, says UBS
Subscribe for More Information
08:54 EDTABBVExpress Scripts says hoping more companies take AbbVie view on opening access
Express Scripts (ESRX) CEO George Paz says AbbVie's (ABBV) Hep C drug compliance was "really high" in trials and that the company was focused on opening up access to its drug with the deal it struck with Express Scripts. Paz believes drug prices are "unsustainable" at recent levels and he believes deals like the one his company struck with AbbVie can be extended to other therapeutic areas. Paz was speaking on CNBC.
08:01 EDTABBVAASLD publishes new recommendations for treating Hepatitis C
Subscribe for More Information
07:07 EDTABBVExpress Scripts and AbbVie to expand access to Viekira Pak
Subscribe for More Information
06:39 EDTABBVHepatitis C deal a blow to biotech bull market, The Street's Feuerstein says
Subscribe for More Information
06:29 EDTABBVGilead drops 4% after Express Scripts picks AbbVie for hepatitis C
Shares of Gilead (GILD) are moving lower in pre-market trading after Express Scripts (ESRX) spokesman Brian Henry told CNBC's Meg Tirrell and other news outlets that the pharmacy benefits manger will exclusively offer AbbVie's (ABBV) recently approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1. Express Scripts will no longer offer competing drugs from Gilead and Johnson & Johnson (JNJ). Shares of AbbVie are rising 6% to $71.50 in pre-market trading while Gilead is down 4% to $104.15. AbbVie discovered part of the Viekira Pak regimen via its ongoing collaboration with Enanta Pharmaceuticals (ENTA). Shares of Enanta are up 7% to $49.96 in pre-open trading.
05:54 EDTABBVStocks with implied volatility movement; ABBV INVN
Stocks with implied volatility movement; AbbVie (ABBV) 30, InvenSense (INVN) 80 according to iVolatility.
05:44 EDTABBVExpress Scripts to offer AbbVie hepatitis C drug exclusively, CNBC reports
Express Scripts (ESRX) will offer AbbVie's (ABBV) just approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1, while excluding competing drugs from Gilead (GILD) and Johnson & Johnson (JNJ), CNBC's Meg Tirrell reports, citing comments from the pharmacy benefits manager's spokesman Brian Henry. Reference Link
05:31 EDTABBVEnanta announces FDA approval for AbbVie VIEKIRA PAK
Enanta (ENTA) has announced that the FDA has approved AbbVie's (ABBV) VIEKIRA PAK for the Treatment of Chronic Genotype 1 Hepatitis C Virus. The VIEKIRA PAK regimen contains Enanta's lead protease inhibitor paritaprevir, formerly ABT-450, and cured 95%-100% of Hepatitis C patients, with less than two percent of patients experiencing virological failure in Phase 3 clinical trials.
December 21, 2014
12:42 EDTABBVEnanta says FDA approval of AbbVie's VIEKIRA PAK triggers $75M milestone payment
Subscribe for More Information
December 19, 2014
17:46 EDTABBVAbbVie confirms FDA approval of VIEKIRA PAK
Subscribe for More Information
14:40 EDTABBVFDA approves Viekira Pak to treat hepatitis C
Subscribe for More Information
11:02 EDTABBVAbbVie receives orphan status for brain metastases treatment
The FDA granted AbbVie orphan status for veliparib, its treatment of brain metastases when used in combination with DNA-damaging agents.
December 18, 2014
09:03 EDTSGENSeattle Genetics initiates Phase 1b trial of SGN-CD33A
Seattle Genetics announced initiation of a phase 1b clinical trial of SGN-CD33A in combination with standard of care chemotherapy, including cytarabine and daunorubicin, for patients with newly diagnosed acute myeloid leukemia. The trial will also evaluate SGN-CD33A in the consolidation setting for AML, both in combination with cytarabine and as a single-agent maintenance regimen. SGN-CD33A is a novel antibody-drug conjugate targeted to CD33 utilizing Seattle Genetics’ newest technology. CD33 is expressed on most AML cells regardless of subtype, cytogenetic abnormality or underlying mutational heterogeneity. SGN-CD33A is also under evaluation in an ongoing phase 1 dose escalation trial as a single-agent or in combination with hypomethylating agents for the treatment of patients who have relapsed AML or have declined intensive frontline therapy. The study is a phase 1b, open-label, multi-center, dose-escalation clinical trial designed to evaluate SGN-CD33A administered in combination with frontline standard of care regimens for induction (cytarabine and daunorubicin) and/or consolidation. In addition, the study will evaluate single-agent SGN-CD33A as a maintenance regimen. The primary endpoints are determination of the maximum tolerated dose and safety profile of SGN-CD33A in these settings. In addition, the trial will evaluate anti-leukemic activity, pharmacokinetics, progression-free survival and overall survival. The phase 1b trial will enroll approximately 90 patients at multiple centers in the United States.
December 11, 2014
10:13 EDTABBVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
08:34 EDTABBVAbbVie downgraded at Morgan Stanley
Subscribe for More Information
07:54 EDTABBVGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
06:29 EDTABBVShire CEO sees no immediate need to spend break-up fee, Reuters reports
Subscribe for More Information
06:20 EDTABBVAbbVie downgraded to Equal Weight from Overweight at Morgan Stanley
December 9, 2014
07:44 EDTABBVAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use